Use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents interim policy guidance
Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases. The use of delamanid in the treatment of MDR-TB was recommended by the World Health Organizat...
| Otros Autores: | |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Geneva :
World Health Organization
2016.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009816689706719 |
Tabla de Contenidos:
- The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents
- 1. Background
- 2. Guideline purpose and target audience
- 3. Guideline development process
- 4. Evidence for policy formulation
- 4.1 Evaluation of paediatric pharmacokinetics data
- 4.2 Evidence for the safety of delamanid in the treatment of MDR-TB
- 4.3 Evidence for the efficacy of delamanid in the treatment of MDR-TB
- 5. Clinical and scientific factors related to the recommendation
- 6. WHO interim policy recommendations for the use of delamanid in children and adolescents
- 7.Implementation considerations
- 8.Updates and further research.
